A Phase 1, open label, dose escalation study of the safety, tolerability and preliminary efficacy of intraperitoneal EGEN-001 in patients with recurrent epithelial ovarian cancer.

Trial Profile

A Phase 1, open label, dose escalation study of the safety, tolerability and preliminary efficacy of intraperitoneal EGEN-001 in patients with recurrent epithelial ovarian cancer.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 27 Feb 2013

At a glance

  • Drugs GEN 1 (Primary)
  • Indications Ovarian cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 27 Feb 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 13 Jul 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top